Aeterna Zentaris Inc. (AEZS): Price and Financial Metrics

Aeterna Zentaris Inc. (AEZS)

Today's Latest Price: $0.35 USD

0.01 (2.73%)

Updated Sep 25 4:00pm

Add AEZS to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 373 in Biotech

See all "A" rated Strong Buy stocks

AEZS Stock Summary

  • AEZS has a market capitalization of $6,818,128 -- more than approximately just 2.6% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at -80.92 for Aeterna Zentaris Inc; that's greater than it is for merely 0.32% of US stocks.
  • As for revenue growth, note that AEZS's revenue has grown -41.6% over the past 12 months; that beats the revenue growth of just 5% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to Aeterna Zentaris Inc, a group of peers worth examining would be APEN, DGLY, ADMS, AZUL, and AAL.
  • AEZS's SEC filings can be seen here. And to visit Aeterna Zentaris Inc's official web site, go to
AEZS Daily Price Range
AEZS 52-Week Price Range

AEZS Stock Price Chart Technical Analysis Charts

AEZS Price/Volume Stats

Current price $0.35 52-week high $1.54
Prev. close $0.34 52-week low $0.33
Day low $0.33 Volume 1,385,997
Day high $0.36 Avg. volume 2,080,446
50-day MA $0.45 Dividend yield N/A
200-day MA $0.77 Market Cap 18.73M

Aeterna Zentaris Inc. (AEZS) Company Bio

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing novel treatments in oncology, endocrinology, and women's health. The company was founded in 1991 and is based in Summerville, South Carolina.

AEZS Latest News Stream

Event/Time News Detail
Loading, please wait...

AEZS Latest Social Stream

Loading social stream, please wait...

View Full AEZS Social Stream

Latest AEZS News From Around the Web

Below are the latest news stories about Aeterna Zentaris Inc that investors may wish to consider to help them evaluate AEZS as an investment opportunity.

Aeterna Zentaris to launch second pivotal study for its lead asset next year

Aeterna Zentaris ([[AEZS]] -1.8%) said it is preparing for Phase 3 (AEZS-130-P02) safety, efficacy study for its lead product macimorelin, and expects to commence the study in Q1 of 2021. The company is currently developing the product for the diagnosis of child-onset growth hormone deficiency ((CGHD)), in collaboration with Novo Nordisk.100-subject...

Seeking Alpha | September 16, 2020

Aeterna Zentaris Provides Corporate Update

– Recently secured funding bolsters cash runway to fund operations and provides significant optionality for growth– Pivotal Phase 3 safety and efficacy study AEZS-130-P02 (“Study P02”) expected to commence in Q1 2021– Ongoing evaluations to expand pipeline seeking to transform into Company with multiple assets in development – Efforts to secure a commercialization partner for macimorelin in Europe and other key global markets continuing CHARLESTON, S.C., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today provided a corporate update.“Over the course of the last year since my appointment as CEO, a tremendous amount has...

Yahoo | September 16, 2020

The Daily Biotech Pulse: AstraZeneca Pauses Coronavirus Vaccine Study, Trillium To Get $25M Pfizer Investment

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 8) Akouos Inc (NASDAQ: AKUS ) Albireo Pharma Inc (NASDAQ: ALB )(announced positive Phase 3 results for odevixibat in a liver disorder called progressive familial intrahepatic cholestasis) Castle Biosciences Inc (NASDAQ: CSTL ) Harmony Biosciences Holdings Inc (NASDAQ: HRMY ) Kura Oncology Inc (NASDAQ: KURA ) Merit Medical Systems, Inc. (NASDAQ: MMSI )(announced sale of manufacturing equipment and associated assets used in its hypotube manufacturing business) X T L Biopharmaceuticals Ltd (NASDAQ: XTLB ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 8) ADiTx Therapeutics Inc (NASDAQ: ADTX ) AEterna Zentaris Inc. (NASDAQ: AEZS )(announced the presentation of data from pediatric study of macimorelin for childhood-o...

Benzinga | September 9, 2020

Aeterna Zentaris to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

\- Live video webcast with CEO, Dr. Klaus Paulini, on Wednesday, September 16th at 11:00 AM EDT - CHARLESTON, S.C., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that Dr. Klaus Paulini, Chief Executive Officer of Aeterna will present at the H.C. Wainwright 22nd Annual Global Investment Conference on Wednesday, September 16, 2020 at 11:00 AM EDT.In addition to the presentation, management will also be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information, please visit the conference website here.A...

Yahoo | September 9, 2020

Aeterna Zentaris Announced Presentation of Positive Results from First Pediatric Study of Macimorelin at the 22nd European Congress of Endocrinology

\- PK and PD profiles of macimorelin for pediatric use were within the expected range and comparable to results observed in adults - \- Data from this study support the choice of 1.0 mg/kg dose of macimorelin for validity testing in a Phase 3 trial, expected to commence in Q1 2021 -CHARLESTON, S.C., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced the presentation of results from its first pediatric study of macimorelin as a growth hormone stimulation test for the evaluation of childhood-onset growth hormone deficiency (“CGHD”) at the 22nd European Congress of Endocrinology (e-ECE 2020), being held September ...

Yahoo | September 8, 2020

Read More 'AEZS' Stories Here

AEZS Price Returns

1-mo -29.78%
3-mo -57.83%
6-mo -36.36%
1-year -68.47%
3-year -83.72%
5-year -96.11%
YTD -61.54%
2019 -69.05%
2018 24.58%
2017 -34.44%
2016 -19.64%
2015 -92.53%

Continue Researching AEZS

Want to see what other sources are saying about Aeterna Zentaris Inc's financials and stock price? Try the links below:

Aeterna Zentaris Inc (AEZS) Stock Price | Nasdaq
Aeterna Zentaris Inc (AEZS) Stock Quote, History and News - Yahoo Finance
Aeterna Zentaris Inc (AEZS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7609 seconds.